<DOC>
	<DOCNO>NCT02520453</DOCNO>
	<brief_summary>Adjuvant Durvalumab v Placebo 1 year complete resection esophageal cancer follow neoadjuvant CCRT .</brief_summary>
	<brief_title>Adjuvant Durvalumab Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm squamous esophageal cancer , irrespective PDL1 status The enrolment do time interval 20 day 56 day complete resection neoadjvuant CCRT ( residual tumor operation ) Clinical tumor stage neoadjuvant CCRT T34N0M0 T14N13M0 Available tumor specimen biomarker analysis acquire neoadjuvant CCRT operation Other PD1 PDL1 inhibitor history Mean QT interval correct heart rate ( QTc ) â‰¥470 ms use Bazett 's correction Current prior use immunosuppressive medication within 28 day first dose MEDI4736 , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid Active prior document autoimmune disease within past 2 year NOTE : Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>